search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Magnesium oxide to reduce prostate motion.


- candidate number2957
- NTR NumberNTR1161
- ISRCTNWordt niet aangevraagd (NVT)
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR18-dec-2007
- Secondary IDs20599 N/A
- Public TitleMagnesium oxide to reduce prostate motion.
- Scientific TitleDouble-blind placebo-controlled randomized study to determine the effectiveness of magnesium oxide to reduce the prostate motion.
- ACRONYMMagnesium oxide to reduce prostate motion
- hypothesisThe hypothesis is that magnesium oxide is effective in reducing the intrafraction motion of the prostate during radiotherapy treatment for prostate cancer.
- Healt Condition(s) or Problem(s) studiedProstate cancer, Prostatic neoplasms
- Inclusion criteriaProstate cancer patients scheduled for external beam radiotherapy using fiducial marker-based position verification.
- Exclusion criteria1. Patients with known severe constipation;
2. Patients who receive laxatives;
3. Patients with a history of abdominal surgery;
4. Patients with known abdominal diseases (M. Crohn, colitis ulcerosa, diverticulitis);
5. Patients with known severe renal failure;
6. Patients who receive tetracyclines, digoxine, iron or ciprofloxacine;
7. Patients with known kidney stones.
- mec approval receivedno
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupFactorial
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-apr-2008
- planned closingdate1-mei-2009
- Target number of participants184
- InterventionsOne group receives a capsule of 500mg magnesium oxide twice a day and the other group receives a placebo capsule twice a day during the radiotherapy treatment.
- Primary outcomeThe main study parameter is the movement of the prostate during a fraction of radiotherapy. The three fiducial markers are being imaged 5 times during one fraction. These 5 images can be used to derive the range of the intrafraction movement of the prostate.
- Secondary outcomeToxicity will be measured by the Common Toxicity Criteria (CTC) version 3.0 (Trotti). The physician in attendance will score the complaints before treatment and acute toxicity will be scored weekly during the treatment and four weeks after the treatment. All symptoms will be registered even if they occur only on one single occasion.


The Quality of Life (QoL) before treatment and after the treatment will be measured by RAND-36 (general health), EORTC QLQ-C30 (+3) (cancer specific) and the EORTC QLQ-PR25 (prostate specific) (Hornbrook, Aaronson, Borghede). The first QoL questionnaire will be hand over to the patient at the department and the second questionnaire will be sent to the patient.


The amount of gas will be counted by delineation of the gas pockets on the CT-scan and MR-scan before the treatment.
- TimepointsBefore radiotherapy, during the 7 weeks radiotherapy treatment and 4 weeks after radiotherapy.
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESdr. I.M. Lips (M.D.)
- CONTACT for SCIENTIFIC QUERIESdr. M. van Vulpen (M.D.)
- Sponsor/Initiator University Medical Center Utrecht (UMCU)
- Funding
(Source(s) of Monetary or Material Support)
University Medical Center Utrecht (UMCU)
- PublicationsN/A
- Brief summaryRationale:
Some institutes use magnesium oxide to reduce the movement of the prostate during radiotherapy treatment, however this treatment is not evidence based. The hypothesis is that magnesium oxide is effective in reducing the intrafraction motion of the prostate during radiotherapy treatment for prostate cancer.


Objective:
Main: reduced intrafraction motion.
Secondary:
1. changed toxicity;
2. change quality of life;
3. reduced gas inside the rectum.


Study design:
Double-blind placebo-controlled randomized intervention study.


Study population:
Prostate cancer patients who are being treated with external beam radiotherapy using fiducial marker-based position verification.


Intervention:
One group receives a capsule of 500mg magnesium oxide twice a day and the other group receives a placebo capsule twice a day during the radiotherapy treatment.


Main study parameters:
Reducing the intrafraction motion of the prostate with 30%.
- Main changes (audit trail)
- RECORD18-dec-2007 - 9-apr-2008


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl